1Hughes M,Micallef-Eynaud P.Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas. Clinical and laboratory haematology . 2006
2Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma[J]. Annals of Hematology . 2008 (3)
3Robert A. Kyle,Morie A. Gertz,Thomas E. Witzig,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Rafael Fonseca,S. Vincent Rajkumar,Janice R. Offord,Dirk R. Larson,Matthew E. Plevak,Terry M. Therneau,Philip R. Greipp.Review of 1027 Patients With Newly Diagnosed Multiple Myeloma[J].Mayo Clinic Proceedings.2003(1)
5R. Manley,J. Monteath,W. N. Patton.Co-incidental presentation of IgA lambda multiple myeloma and pleural involvement with IgM kappa non-Hodgkin’s lymphoma. Clinical & Laboratory Haematology . 1999
6Kim Yu Jin,Kim Su Jin,Min Kwangseon,Kim Ho Young,Kim Hyo Jung,Lee Young Kyung,Zang Dae Young.Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature. Acta Haematologica . 2008
5UK Myeloma Forum. Britsh Sommittee for Standards in Huematology. Diagnosis and management of multiple myeloma. Br J Haematol, 2001 ; 115 ;522 - 540.
6Blade J, Samson D, Reece D, et al. Criteria for evaluating disease reponse and progression in patients with multiple myeloma treated by high-dose tgerapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol,1998 ;102:1115 - 1123.
7Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 2003 ; 101:2377 - 2380.
8Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res,2003 ;9 : 1136 - 1144.
9Kropff MH, Bispinga G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res, 2005 ;29:587 -590.
10BLADE J,LUST J A,KYLE R A.Immunoglobulin D multiple myeloma:presenting features,response to therapy,and survival in a series of 53 cases[J].J Clin Oncol,1994,12:2398-2404.
2Kamble R, Wilson CS, Fassas A, et al. Malignant pleural effusion of multiple myeloma : prognostic factors and outcome [ J ] . Leuk Lymphoma, 2005, 46 ( 8 ) : 1137-1142.
3Kim YJ, Kim SJ, Min K, et al. Multiple myeloma with myelomatous pleural effusion : a ease report and review of the literature [ J ] . Aeta Haematol, 2008, 120 (2): 108-111.
4Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions : the diagnostic separation of transudates and exudates [ J ] . Ann Intern Med, 1972, 77 (4):507-513.
5Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications [ J ] . Blood, 2011, 117 ( 19 ) : 5019- 5032.
6Oudart JB, Maquart FX, Semouma O, et al. Pleural effusion in a patient with multiple myeloma [ J ] . Clin Chem, 2012, 58 ( 4 ) : 672-674.
7Jiang AG, Yang YT, Gao XY, et al. Bilateral pleural effusion as an initial manifestation of multiple myeloma : A case report and literature review [J]. Exp Ther Med, 2015, 9 ( 3 ) : 1040-1042.
8Cho YU, Chi HS, Park C J, et al. Myelomatous pleural effusion : a case series in a single institution and literature review [ J ] . Korean J Lab Med, 2011, 31 (4): 225-230.
9Xu XL, Shen YH, Shen Q, et al. A case of bilateral pleural effusion as the first sign of multiple myeloma [ J ] . Eur J Med Res, 2013, 18 (1):7.
10A1-Farsi K, A1-Haddabi I, AI-Riyami N, et al. Myelomatous pleural effusion : case report and review of the literature [ J ] . Sultan Qaboos Univ MedJ, 2011, 11 (2) : 259-264.
